Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Cogent Biosciences Inc is a biotechnology business based in the US. Cogent Biosciences shares (COGT) are listed on the NASDAQ and all prices are listed in US Dollars. Cogent Biosciences employs 15 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $6.79 |
|---|---|
| 52-week range | $5.83 - $11.76 |
| 50-day moving average | $8.65 |
| 200-day moving average | $8.25 |
| Wall St. target price | $22.50 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-4.93 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $6.79 from 2022-01-27
| 1 week (2022-01-21) | -11.24% |
|---|---|
| 1 month (2021-12-24) | N/A |
| 3 months (2021-10-28) | -20.86% |
| 6 months (2021-07-28) | 7.61% |
| 1 year (2021-01-28) | -25.30% |
|---|---|
| 2 years (2020-01-28) | 614.89% |
| 3 years (2019-01-28) | 79.16% |
| 5 years (2017-01-24) | N/A |
| Gross profit TTM | $-15,967,000 |
|---|---|
| Return on assets TTM | -20.12% |
| Return on equity TTM | -37.47% |
| Profit margin | 0% |
| Book value | $2.81 |
| Market capitalisation | $301.7 million |
TTM: trailing 12 months
We're not expecting Cogent Biosciences to pay a dividend over the next 12 months.
Cogent Biosciences's shares were split on a 1:4 basis on 8 November 2020. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cogent Biosciences shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Cogent Biosciences shares which in turn could have impacted Cogent Biosciences's share price.
Cogent Biosciences, Inc. , a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. Cogent Biosciences, Inc. has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of CGT9486 and CGT0206 inhibitors. The company was formerly known as Unum Therapeutics Inc.
Five major factors contribute to the continued bull run of Bitcoin, ARK says, including growing adoption and long-term focus of investors.
Lido’s liquid staking allows investors holding LUNA and less than 32 ETH to reap the rewards of DeFi staking.
Downturns often let you buy fundamentally strong stocks at bargain prices, but mind the fundamentals and consider these 3 rules.
The crypto market wiped out $1.5 trillion in value in just three months.
Bitcoin breached the $40,000 price level and may plummet lower as Russia signals a potential ban.
Cardano’s first metaverse project is available to investors now — if you can find a piece of digital land on sale. Plots sold fast despite the project’s early stage limitations.
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.